CoreFirst Bank & Trust Makes New $83,000 Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

CoreFirst Bank & Trust purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 900 shares of the biopharmaceutical company’s stock, valued at approximately $83,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Kingsview Wealth Management LLC boosted its stake in Gilead Sciences by 8.9% during the 3rd quarter. Kingsview Wealth Management LLC now owns 19,923 shares of the biopharmaceutical company’s stock worth $1,670,000 after acquiring an additional 1,628 shares during the last quarter. Larson Financial Group LLC raised its holdings in Gilead Sciences by 79.2% in the third quarter. Larson Financial Group LLC now owns 7,835 shares of the biopharmaceutical company’s stock worth $657,000 after purchasing an additional 3,464 shares during the period. Independent Advisor Alliance boosted its position in shares of Gilead Sciences by 1.2% during the third quarter. Independent Advisor Alliance now owns 23,730 shares of the biopharmaceutical company’s stock worth $1,990,000 after purchasing an additional 270 shares in the last quarter. Truvestments Capital LLC acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at $126,000. Finally, FMR LLC increased its position in shares of Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after buying an additional 14,680,161 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Up 1.1 %

Shares of GILD stock opened at $107.89 on Wednesday. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The stock has a market cap of $134.36 billion, a price-to-earnings ratio of 291.59, a PEG ratio of 0.71 and a beta of 0.21. The firm’s 50-day moving average is $104.35 and its 200-day moving average is $94.36. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.93%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio is 854.05%.

Wall Street Analysts Forecast Growth

GILD has been the topic of several recent analyst reports. Morgan Stanley lifted their target price on Gilead Sciences from $123.00 to $130.00 and gave the stock an “overweight” rating in a report on Tuesday, March 11th. Bank of America boosted their price objective on Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Piper Sandler raised their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Finally, Royal Bank of Canada raised their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $104.52.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 302,785 shares of company stock worth $30,503,250 over the last quarter. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.